Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

詳細情報 詳細情報について

• CRID

  1363951793245309056

• DOI

  10.1038/leu.2016.5

• ISSN

  14765551

  08876924

• Web Site

  http://www.nature.com/articles/leu20165.pdf

  http://www.nature.com/articles/leu20165

• データソース種別

  • Crossref